CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 604 enrolled
Drug / intervention
clindamycin phosphate vaginal cream 2% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02210689
NCT02210689Phase 3Completed

A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women

Actavis Inc.·interventional·Posted Aug 7, 2014·Updated Jan 28, 2020

In Brief

A Phase 3 clinical trial evaluating clindamycin phosphate vaginal cream 2% and placebo for BACTERIAL VAGINOSIS and 4 related conditions. Completed, enrolled 604 participants across 18 sites in 3 countries.

Detailed Summary

A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Clindamycin phosphate vaginal cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and both active treatments to a placebo control in the treatment of bacterial vaginosis in non-pregnant women.

Study Details

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 7, 2014
Enrollment StartJan 1, 2014
Primary CompletionOct 1, 2014
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.9 years ago

Interventions

clindamycin phosphate vaginal cream 2%drug

placeboother

vehicle used as placebo